Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Praxis Precision Medicines, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001689548-26-000083
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | $69,416 | $63,006 | $147,403 | $123,812 |
| General and administrative | 27,488 | 13,061 | 55,361 | 26,983 |
| Total operating expenses | 96,904 | 76,067 | 202,764 | 150,795 |
| Loss from operations | (96,904) | (76,067) | (202,764) | (150,795) |
| Other income: | ||||
| Other income, net | 13,184 | 4,940 | 26,483 | 10,372 |
| Total other income | 13,184 | 4,940 | 26,483 | 10,372 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Praxis Precision Medicines, Inc.'s R&D?
- Praxis Precision Medicines, Inc. (PRAX) reported R&D of $69.42M in Q2 2026.
- How has Praxis Precision Medicines, Inc.'s R&D changed year-over-year?
- Praxis Precision Medicines, Inc.'s R&D increased by 10.2% year-over-year, from $63.01M to $69.42M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s R&D?
- Over 4 years (2021 to 2025), Praxis Precision Medicines, Inc.'s R&D has grown at a 22.1% compound annual growth rate (CAGR), from $120.26M to $267.12M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Praxis Precision Medicines, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude